Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Increasing Possibility of Success by Expanded Antibody Repertoires with Lambda Light Chain - Immunocan Launches New Mouse Strain of Fully Human Antibody Platform: ImmuMab® HKL Mouse 2024-07-17 21:50
111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024 2024-07-17 13:31
GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities 2024-07-17 10:38
Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks 2024-07-16 23:55
FDA Grants Orphan Drug Designation to 7MW3711 2024-07-16 22:00
Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials 2024-07-16 20:00
Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC 2024-07-15 22:00
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer 2024-07-15 19:00
First Patient Dosed in Phase I Clinical Trial of YOLT-201 2024-07-11 20:11
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC 2024-07-11 20:00
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy' 2024-07-11 14:07
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year 2024-07-10 13:30
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development 2024-07-08 22:00
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease 2024-07-08 17:23
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME 2024-07-08 17:00
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors 2024-07-08 16:28
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial 2024-07-08 13:41
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC) 2024-07-05 21:00
IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy 2024-07-05 16:30
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis 2024-07-05 16:07
1 11 12 13 14 15 165